Results 21 to 30 of about 46,090 (276)
The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer [PDF]
International Journal of Molecular SciencesDicer, a cytoplasmic type III RNase, is essential for the maturation of microRNAs (miRNAs) and is implicated in cancer progression and chemoresistance. Our previous research demonstrated that phosphorylation of Dicer at S1016 alters miRNA maturation and glutamine metabolism, contributing to gemcitabine (GEM) resistance in pancreatic ductal ...
Ching-Feng Chiu +5 more
openaire +3 more sources
Neoplasia: An International Journal for Oncology Research, 2010 Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer. Our previous experimental chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the ...
Wolfgang Hagmann +2 more
doaj +2 more sources
Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer [PDF]
The Journal of Qazvin University of Medical Sciences, 2017 Pancreatic cancer is one the most malignant cancers in human. A great percentage of patients die annually due to lack of early detection as well as efficient treatment strategies. Only five-year survival rate is still only seen in 5% of patients.
A. Rajabpour +2 more
doaj +1 more source
Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]
Research in Oncology, 2021 Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei +4 more
doaj +1 more source
EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer
BMC CancerBackground Gemcitabine is a cornerstone drug for the treatment of all stages of pancreatic cancer and can prolong the survival of patients with pancreatic cancer, but resistance to gemcitabine in pancreatic cancer patients hinders its efficacy.
Zhe Yang +5 more
doaj +2 more sources
Cell Death and Disease, 2021 The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun +5 more
doaj +1 more source
APOBEC3 upregulation drives gemcitabine resistance [PDF]
Nature CancerJohn Maciejowski, Taha Mohamed
openaire +3 more sources
Molecular Cancer, 2022 Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu +12 more
doaj +1 more source
Biomedicines, 2022 Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek +2 more
doaj +1 more source
WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition
Drug Discoveries & Therapeutics, 2022 Gemcitabine is widely used in the clinic as a first-line antitumor agent. However, intrinsic and acquired resistance hinders its wide clinical application. In this study, a gemcitabine prodrug nominated as WRQ-2 was designed and synthesized by conjugating gemcitabine with the indole-3-methanol analogue OSU-A9 through a carbamate linkage.
Wang, Ruquan +3 more
openaire +2 more sources